{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T23:03:29Z","timestamp":1762211009569,"version":"3.40.5"},"reference-count":33,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T00:00:00Z","timestamp":1619654400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vox Sanguinis"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:sec><jats:title>Background and objectives<\/jats:title><jats:p>Access to large pools of healthy adult donors advantageously positions blood component providers to undertake anti\u2010SARS\u2010CoV\u20102 seroprevalence studies. While numerous seroprevalence reports have been published by blood operators during the COVID\u201019 pandemic, details on the assay used has not been well documented. The objectives of this study were to evaluate the diversity of assays being used by blood operators and assess how this may affect seroprevalence estimates.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>We surveyed 49 blood component providers from 39 countries. Questionnaire included information on the number and identity of assays used, the detected immunoglobulin(s) and target antigen, and performance characteristics (sensitivity, specificity).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Thirty\u2010eight of the 49 contacted blood suppliers provided at least partial responses. The results indicate that 19 commercial and five in\u2010house serology assays have been used by surveyed blood operators. The Abbott SARS\u2010CoV\u20102 IgG assay was the most commonly used kit and utilized by 15 blood suppliers. Two assays did not detect IgG, but detected either IgM\/IgA or IgM. 68\u00b72% of assays targeted the spike protein and 50% the nucleocapsid protein, while 18\u00b72% targeted both viral proteins. The sensitivity and specificity of IgG\u2010specific assays ranged from 71\u00b79% to 100% and from 96\u00b72% to 100%, respectively. As of 18 October 2020, the seroprevalence was below 5% in 10 of 14 countries reporting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our results highlight the diversity of assays being used. Analyses comparing blood donor seroprevalence across countries should consider assay characteristics with optimization of signal\/cut\u2010off ratios and consistent methodology to adjust for waning antibody.<\/jats:p><\/jats:sec>","DOI":"10.1111\/vox.13100","type":"journal-article","created":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T17:01:41Z","timestamp":1619715701000},"page":"946-954","source":"Crossref","is-referenced-by-count":7,"title":["An international comparison of anti\u2010SARS\u2010COV\u20102 assays used for seroprevalence surveys from blood component providers"],"prefix":"10.1111","volume":"116","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1748-4198","authenticated-orcid":false,"given":"Antoine","family":"Lewin","sequence":"first","affiliation":[{"name":"Medical Affairs &amp; Innovation H\u00e9ma\u2010Qu\u00e9bec Montreal QC Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2519-1109","authenticated-orcid":false,"given":"Steven J.","family":"Drews","sequence":"additional","affiliation":[{"name":"Microbiology Canadian Blood Services Edmonton AB Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryanne","family":"Lieshout\u2010Krikke","sequence":"additional","affiliation":[{"name":"Department of Medical Affairs Sanquin Blood Supply Foundation Amsterdam Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Erikstrup","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology Aarhus University Hospital Aarhus Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sahar","family":"Saeed","sequence":"additional","affiliation":[{"name":"Epidemiology &amp; Surveillance Canadian Blood Services Ottawa ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3446-8248","authenticated-orcid":false,"given":"Helen","family":"Faddy","sequence":"additional","affiliation":[{"name":"School of Health and Behavioural Sciences University of the Sunshine Coast Petrie QLD Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samra","family":"Uzicanin","sequence":"additional","affiliation":[{"name":"Epidemiology &amp; Surveillance Canadian Blood Services Ottawa ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6251-366X","authenticated-orcid":false,"given":"Brian","family":"Custer","sequence":"additional","affiliation":[{"name":"Research &amp; Scientific Programs Vitalant San Francisco CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5332-2789","authenticated-orcid":false,"given":"Sheila F","family":"O\u2019Brien","sequence":"additional","affiliation":[{"name":"Epidemiology &amp; Surveillance Canadian Blood Services Ottawa ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the Surveillance, Risk Assessment, Policy, the Virology Sub\u2010groups of the ISBT Transfusion Transmitted Infectious Diseases Working Party","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,4,29]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.7326\/M20-3012"},{"key":"e_1_2_7_3_1","doi-asserted-by":"crossref","unstructured":"SubramanianR HeQ PascualM.Quantifying asymptomatic infection and transmission of COVID\u201019 in New York City using observed cases serology and testing capacity. medRxiv[Internet]. 2020 Oct 20 [cited 2020 Dec 7];2020.10.16.20214049. Available from:https:\/\/www.medrxiv.org\/content\/10.1101\/2020.10.16.20214049v1","DOI":"10.1101\/2020.10.16.20214049"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18272-4"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0913-5"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.12688\/wellcomeopenres.15927.1"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008367"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32009-2"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.33706"},{"key":"e_1_2_7_10_1","unstructured":"Center for Devices and Radioogical Health U.S. Food & Drug Administration.Individual EUAs for Serology Tests for SARS\u2010CoV\u20102[Internet]. U.S. Food & Drug Administration (FDA).2020. Available from:https:\/\/www.fda.gov\/medical\u2010devices\/coronavirus\u2010disease\u20102019\u2010covid\u201019\u2010emergency\u2010use\u2010authorizations\u2010medical\u2010devices\/vitro\u2010diagnostics\u2010euas#individual\u2010serological"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30120-1"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00797-20"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02148-20"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2020.25.23.2000980"},{"key":"e_1_2_7_15_1","first-page":"CD013652","article-title":"Antibody tests for identification of current and past infection with SARS\u2010CoV\u20102","volume":"6","author":"Deeks JJ","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m2516"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2020.1826362"},{"key":"e_1_2_7_18_1","article-title":"Research initiatives of blood services worldwide in response to the covid\u201019 pandemic","author":"O\u2019Brien SF","year":"2020","journal-title":"Vox Sang"},{"key":"e_1_2_7_19_1","unstructured":"Center for Devices and Radiological Health (CDRH).EUA Authorized Serology Test Performance[Internet]. U.S. Food & Drug Administration (FDA). FDA;2020[cited 2020 Nov 23]. Available from:https:\/\/www.fda.gov\/medical\u2010devices\/coronavirus\u2010disease\u20102019\u2010covid\u201019\u2010emergency\u2010use\u2010authorizations\u2010medical\u2010devices\/eua\u2010authorized\u2010serology\u2010test\u2010performance"},{"key":"e_1_2_7_20_1","unstructured":"WorldOMeter.COVID\u201019 Coronavirus Pandemic \u2010 WorldOMeter[Internet]. WorldOMeter2020. [cited 2020 Jun 15]. Available from:https:\/\/www.worldometers.info\/coronavirus\/."},{"key":"e_1_2_7_21_1","unstructured":"PostN EddyD HuntleyC et\u00a0al.Antibody response to SARS\u2010CoV\u20102 infection in humans: A systematic review. medRxiv [Internet].2020[cited 2020 Dec 14];2020.08.25.20178806. Available from:https:\/\/www.medrxiv.org\/content\/10.1101\/2020.08.25.20178806v1."},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2020.1761267"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1099\/jgv.0.001439"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18450-4"},{"key":"e_1_2_7_25_1","doi-asserted-by":"crossref","unstructured":"SrivastavaA TamrakarV MoradhvajM et\u00a0al.Geographical variation in COVID\u201019 cases prevalence recovery and fatality rate by phase of national lockdown in India March 14\u2010May 29 2020. medRxiv [Internet]. 2020 Jun 5 [cited 2020 Dec 7];2020.06.04.20122028. Available from:https:\/\/www.medrxiv.org\/content\/10.1101\/2020.06.04.20122028v1.","DOI":"10.1101\/2020.06.04.20122028"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31482-3"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30634-4"},{"key":"e_1_2_7_28_1","unstructured":"BussLF PreteCA AbrahimCM et\u00a0al.COVID\u201019 herd immunity in the Brazilian Amazon. medRxiv [Internet].2020[cited 2020 Nov 19];2020.09.16.20194787. Available from:https:\/\/www.medrxiv.org\/content\/10.1101\/2020.09.16.20194787v1."},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2020.25.10.2000180"},{"key":"e_1_2_7_30_1","unstructured":"CarsettiR ZaffinaS MortariEP et\u00a0al.Different innate and adaptive immune response to SARS\u2010CoV\u20102 infection of asymptomatic mild and severe cases. medRxiv [Internet].2020[cited 2020 Dec 4];2020.06.22.20137141. Available from:https:\/\/www.medrxiv.org\/content\/10.1101\/2020.06.22.20137141v2."},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0965-6"},{"volume-title":"StatPearls","year":"2021","author":"Tenny S","key":"e_1_2_7_32_1"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2912-6"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2020.25.16.2000421"}],"container-title":["Vox Sanguinis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vox.13100","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/vox.13100","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vox.13100","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T16:25:22Z","timestamp":1692635122000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/vox.13100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,29]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.1111\/vox.13100"],"URL":"https:\/\/doi.org\/10.1111\/vox.13100","archive":["Portico"],"relation":{},"ISSN":["0042-9007","1423-0410"],"issn-type":[{"type":"print","value":"0042-9007"},{"type":"electronic","value":"1423-0410"}],"subject":[],"published":{"date-parts":[[2021,4,29]]}}}